Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations

Inclusion Criteria

• •Any patient harboring a brain AVM (ruptured or unruptured) in whom TVE is considered a promising but yet unproven therapeutic option by the participating clinicians can be submitted to the Case Selection Committee.
• •Patients must be in stable, non-urgent clinical condition, with the acute phase of the AVM rupture resolved (where applicable).
• •Case must be approved by the CSC.
• •Notes on potentially suitable cases:
• •1. Current indications may include (but are NOT restricted to) brain AVMs with a small \<3 cm nidus (or small residual nidus), with a single draining vein, and for which curative treatment can be attained with one or at most two treatment sessions.
• •2. Physicians are not required to submit cases prior to any or all treatment; a case can be submitted to the CSC for consideration after previous treatments (including previous arterial embolization sessions) have been performed. The timing of the submission of the case will be left to individual operators. Previously treated AVMs (by any other modality: embolization/surgical resection/radiosurgery) are not excluded from TATAM.